Oral News and Research

RSS

Positive clinical trial results of EndoBarrier Gastrointestinal Liner device announced

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced initial, positive results from a clinical trial evaluating 12 months of treatment with the EndoBarrier™ Gastrointestinal Liner.

3 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

New dental device takes fear and pain out of anesthetic injections

DentalVibe™ a new dental device now on the market takes the fear and pain out of dental injections. The product design firm, Bresslergroup, teamed with Dr. Steven G. Goldberg, DDS, to design the easy to use tool. Research shows that fear of a painful anesthetic injection keeps 50% of the patient population away from the dentist.

3 Mar 2010

Data demonstrating effectiveness of KALBITOR to treat acute HAE presented at AAAAI 2010 Annual Meeting

Data demonstrating the effectiveness of KALBITOR (ecallantide) to treat hereditary angioedema (HAE) acute attacks by primary attack location were provided in an oral presentation yesterday at the American Academy of Allergy, Asthma and Immunology 2010 Annual Meeting in New Orleans.

3 Mar 2010

IntelliDose introduces new, integrated clinical software for medical oncology practices

IntelliDose®, a leading clinical software to manage medical oncology practices, today introduces IntelliScribe™ – a new, fully integrated module in the IntelliDose workflow – to electronically generate prescriptions at any point in the chemotherapy order writing process.

3 Mar 2010

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Geron Corporation today announced several presentations at the American Association for Cancer Research Special Conference on The Role of Telomeres and Telomerase in Cancer Research held in Fort Worth, TX between February 27th and March 1st.

3 Mar 2010

Phase III study results of Merck's allergy immunotherapy tablet

In new data from a Phase III study in 345 children and adolescents (ages 5-17 years), patients with grass pollen allergic rhinoconjunctivitis treated with Merck's investigational sublingual grass (Phleum Pratense) allergy immunotherapy tablet (AIT) showed a 26 percent greater improvement in the total combined score (daily symptom score and daily medication score), compared to patients receiving placebo

3 Mar 2010

EMA accepts the filing of Lux Biosciences' MAA for Luveniq

Lux Biosciences, Inc. today announced that the European Medicines Agency has accepted the filing of the company’s Marketing Authorization Application (MAA) for the company’s lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.

3 Mar 2010

Rigel Pharmaceuticals reports net loss of $0.48 per share for fourth-quarter 2009

Rigel Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009.

2 Mar 2010

Stress increases resistance to influenza infection

A new study using mice suggests that a repeated stressful situation that triggers the animals' natural "fight-or-flight" response may actually enhance their ability to fight disease when re-exposed to the same pathogen.

2 Mar 2010

Thomson Reuters introduces new Pharmacy Intervention solution for hospitals

Thomson Reuters announced today the launch of its new Pharmacy Intervention solution for hospitals.

2 Mar 2010

Majority of prediabetic patients are not adopting preventive measures to avoid diabetes

Although it is known that diabetes can be prevented or delayed among adults at high risk through modest weight loss and increased physical activity, a study published in the April 2010 issue of the American Journal of Preventive Medicine revealed that only about half of U.S. adults with prediabetes reported that in the past year they tried to lose weight or exercise more.

2 Mar 2010

Acorda Therapeutics' AMPYRA now available in the U.S. and Puerto Rico

Acorda Therapeutics, Inc. today announced that AMPYRA™ (dalfampridine) Extended Release Tablets, 10 mg is now available by prescription in the United States and Puerto Rico. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is indicated for use in all types of MS, and can be used either alone or with existing therapies, including disease-modifying agents.

1 Mar 2010

COMP issues positive opinion for Æterna Zentaris' perifosine orphan medicinal product designation

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation for its compound perifosine from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for the treatment of multiple myeloma.

1 Mar 2010

Uroplasty's Urgent PC Neuromodulation System SUmiT Trial demonstrates effectiveness of PTNS

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results of the SUmiT Trial of its Urgent® PC Neuromodulation System that will be published in the April 2010 print edition of THE JOURNAL OF UROLOGY® and is now available on line.

1 Mar 2010

Oral immunotherapy promising for egg allergies, SLIT for milk allergies

Children with egg allergies who consume increasingly higher doses of egg protein - the very nutrient they react to - appear to gradually overcome their allergies, tolerating eggs better over time and with milder symptoms, according to research conducted at Johns Hopkins Children's Center and elsewhere.

1 Mar 2010

Short-term dose of losartan-M6PHSA reduces liver inflammation and fibrosis: Study

A recent study found that rats with advanced fibrosis that were administered a short-term dose of losartan-M6PHSA had reduced liver inflammation and fibrosis. Those animals treated with oral losartan alone did not experience a similar reduction in disease activity. Results of this study appear in the March issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

1 Mar 2010

ADMET tester Absorption Systems joins Society of Toxicology as Affiliate

Absorption Systems, a leader in testing drugs for ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity), has joined the Society of Toxicology, the premier global professional association of toxicologists, as an SOT Affiliate. The firm, a contract research organization, has more than a decade of experience assisting pharmaceutical and biotechnology companies in determining which compounds in development should be advanced into clinical testing.

27 Feb 2010

Prevention of recurrent strokes: Antiplatelet drug cilostazol effective and safer than aspirin

The antiplatelet drug cilostazol — used in the United States to treat leg pain associated with peripheral vascular disease — was more effective and safer than aspirin at preventing recurrent strokes in a Japanese trial presented as late-breaking science at the American Stroke Association's International Stroke Conference 2010.

27 Feb 2010

Henry Schein signs strategic partnership to distribute Brain-Pad's NatureZone UV/Ozone oral sanitizer

Henry Schein, Inc., the largest distributor of health care products and services to office-based practitioners, today announced a new strategic partnership with Brain-Pad. Under a new five year agreement, Henry Schein Dental will be the exclusive professional dental distributor in the U.S. and Canada for the NatureZone™ one-touch UV/Ozone oral appliance sanitizer.

26 Feb 2010

Oral News and Research

Positive clinical trial results of EndoBarrier Gastrointestinal Liner device announced

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

New dental device takes fear and pain out of anesthetic injections

Data demonstrating effectiveness of KALBITOR to treat acute HAE presented at AAAAI 2010 Annual Meeting

IntelliDose introduces new, integrated clinical software for medical oncology practices

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Phase III study results of Merck's allergy immunotherapy tablet

EMA accepts the filing of Lux Biosciences' MAA for Luveniq

Rigel Pharmaceuticals reports net loss of $0.48 per share for fourth-quarter 2009

Stress increases resistance to influenza infection

Thomson Reuters introduces new Pharmacy Intervention solution for hospitals

Majority of prediabetic patients are not adopting preventive measures to avoid diabetes

Acorda Therapeutics' AMPYRA now available in the U.S. and Puerto Rico

COMP issues positive opinion for Æterna Zentaris' perifosine orphan medicinal product designation

Uroplasty's Urgent PC Neuromodulation System SUmiT Trial demonstrates effectiveness of PTNS

Oral immunotherapy promising for egg allergies, SLIT for milk allergies

Short-term dose of losartan-M6PHSA reduces liver inflammation and fibrosis: Study

ADMET tester Absorption Systems joins Society of Toxicology as Affiliate

Prevention of recurrent strokes: Antiplatelet drug cilostazol effective and safer than aspirin

Henry Schein signs strategic partnership to distribute Brain-Pad's NatureZone UV/Ozone oral sanitizer

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News